Hormone replacement therapy and risk of epithelial ovarian cancer

British Journal of Cancer

Volumn 81, Issue 3, 1999, Pages 559-563

  Purdie, D M ^a,f   Bain, C J ^a   Siskind, V ^a   Russell, P ^b   Hacker, N F ^c   Ward, B G ^a   Quinn, M A ^d   Green, A C ^e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c ROYAL HOSPITAL FOR WOMEN   (Australia)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Case control study; Oestrogen replacement therapy; Ovarian neoplasms

Indexed keywords

CONTRACEPTIVE AGENT; ESTROGEN;

ARTICLE; AUSTRALIA; CANCER STATISTICS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DATA ANALYSIS; ENDOMETRIUM CANCER; EPITHELIUM TUMOR; ESTROGEN THERAPY; FEMALE; FEMALE GENITAL SYSTEM; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INTERVIEW; MAJOR CLINICAL STUDY; MEDICAL RECORD; OVARY TUMOR; PELVIS SURGERY; PRIORITY JOURNAL; QUESTIONNAIRE; UTERINE TUBE LIGATION;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; DRUG INTERACTIONS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYSTERECTOMY; INCIDENCE; MIDDLE AGED; MIXED TUMOR, MESODERMAL; MIXED TUMOR, MULLERIAN; NEW SOUTH WALES; ODDS RATIO; OVARIAN NEOPLASMS; POSTMENOPAUSE; POSTOPERATIVE COMPLICATIONS; PROGESTINS; QUEENSLAND; RISK; STERILIZATION, TUBAL; VICTORIA;

EID: 0032837282     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690731     Document Type: Article

References (28)

1. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10
2. Booth M, Beral V and Smith P (1989) Risk factors for ovarian cancer: a case-control study. Br J Cancer 60: 592-598
3. Cramer DW, Hutchinson GB, Welch WR, Scully RE and Ryan KJ (1983) Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 71: 711-716
4. Dennerstein L, Shelly J, Smith AMA and Ryan M (1994) Hysterectomy experience among mid-aged Australian women. Med J Aust 161: 311-313
5. Faulkner RL and Riemenschneider EA (1945) Reactivation of endometriosis by stilbestrol therapy. Am J Obstet Gynecol 105: 560
6. Garg PP, Kerlikowske K, Subak L and Grady D (1998) Hormone replacement therapy and risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92: 472-479
7. Grady D, Gebretsadik T, Kerlikowske K, Ernster V and Petitti D (1995) Hormone replacement therapy and endormetrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304-313
8. Green A, Purdie D, Green L, Dick M-L, Bain C and Siskind V (1997a) Validity of self-reported hysterectomy and tubal sterilisation. Aust N Z J Public Health 21: 337-340
9. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M and Ward B (1997b) Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Int J Cancer 71: 948-951
10. Green PK, Weiss NS, McKnight B, Voigt LF and Beresford SAA (1996) Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 7: 575-580
11. Greven KM and Corn BW (1997) Endometrial cancer. Curr Probl Cancer 21: 65-127
12. Hartge P, Hoover R, McGowan L, Lesher L and Norris HJ (1988) Menopause and ovarian cancer. Am J Epidemiol 127: 990-998
13. Hempling RE, Wong C, Piver MS, Natarajan N and Mettlin CJ (1997) Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 89: 1012-1016
14. International Agency for Research on Cancer (1987) Overall Evaluations of Carcinogenicity: an Updating of IARC Monographs, Vol 1-42. IARC Monogr Eval Carcinog Risk Chem Hum (Suppl 7). pp 280-283. IARC: Lyon
15. Kaufman DW, Kelly JP, Welch WR, Rosenberg L, Stolley PD, Warshauer ME, Lewis J, Woodruff J and Shapiro S (1980) Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 130: 1142-1151
16. La Vecchia C, Liberati A and Franceschi S (1982) Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 69: 1207
17. Metzger DA and Haney AF (1989) Etiology of endometriosis. Obstet Gynecol Clin North Am 16: 1-14
18. Paganini-Hill A, Ross RK and Henderson BE (1989) Endometrial cancer and patterns of use of oestrogen replacement therapy: a cobort study. Br J Cancer 59: 445-447
19. Paulson RJ (1997) Fertility drugs and ovarian epithelial cancer: the endometriosis hypothesis. J Assist Reprod Genet 14: 228-230
20. Purdic D, Green A, Bain C, Siskind V, Ward B, Hacker N, Quinn M, Wright G, Russell P and Susil B (1995) Reproductive and other factors and risk of epithelial overian cancer: an Australian case-control study. Int J Cancer 62: 678-684
21. Risch HA (1996) Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 63: 254-257
22. Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ and Health CW (1995) Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 141: 828-835
23. Russell P (1994) Surface epithelial-stromal tumors of the ovary. In: Blanstein's Pathology of the Female Genital Tract, 4th edn. Kurman RJ (ed). pp. 705-782. Springer Verlag: New York
24. Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Nikrui N and Goff BA (1996) Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 60: 238-244
25. Scully RE (1977) Ovarian tumors. Am J Pathol 87: 686-720
26. Smith M and McCartney AJ (1985) Occult, high-risk endometrial cancer. Gynecol Oncol 22: 154
27. Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM and Daling JR (1982) Noncontraceptive estrogen use and the ocurrence of ovarian cancer. J Natl Cancer Inst 68: 95-98
28. Whittemore AS, Harris R, Itnyre J and The Collaborative Ovarian Cancer Group (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136: 1184-1203